FibroBiologics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
FBLG Nasdaq 2830 fibrobiologics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for FibroBiologics, Inc.

FibroBiologics Announces Closing of up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Jun 29th, 2026 2:01 pm
FibroBiologics Announces up to $9.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules - Jun 26th, 2026 6:30 am
FibroBiologics Receives Notice of Allowance for U.S. Patent Covering Topical Fibroblast Spheroid Therapy for Wound Healing - Jun 22nd, 2026 6:30 am
FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers - Jun 16th, 2026 6:30 am
FBLG: Phase 1/2 Trial of CYWC628 Underway - Jun 4th, 2026 4:02 am
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers - Jun 3rd, 2026 5:00 am
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial - Jun 3rd, 2026 4:46 am
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data? - Jun 2nd, 2026 7:57 am
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting - May 22nd, 2026 6:30 am
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics - May 18th, 2026 6:30 am
FibroBiologics Advancing Development of a Fibroblast Treatment for Hantavirus - May 11th, 2026 6:30 am
FibroBiologics CEO Issues Letter to Shareholders - May 5th, 2026 6:30 am
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring - May 4th, 2026 2:01 pm
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial - May 4th, 2026 6:30 am
FibroBiologics Reports Q1 2026 Financial Results and Provides Corporate Update - Apr 30th, 2026 3:55 pm
FibroBiologics Announces Poster Presentation at the Society for Investigative Dermatology Annual Meeting 2026 - Apr 30th, 2026 6:30 am
FibroBiologics Compliant with All Nasdaq Listing Requirements - Apr 20th, 2026 2:01 pm
FibroBiologics Presents Novel Thymus Organoid Platform to Combat Age-Related Immune Decline at Keystone Symposia on Aging and Immunity - Apr 10th, 2026 6:30 am
FibroBiologics Announces Closing of $3 Million Public Offering - Apr 2nd, 2026 2:01 pm
FBLG: Advancing Fibroblast Therapy on Multiple Fronts - Apr 1st, 2026 5:40 am